Profile
Andrew King is currently Chief Scientific Officer at Jade Biosciences, Inc. (United States) since 2024 and President-Research & Development at Jade Biosciences, Inc. starting in 2026.
Former positions include Chief Scientific Officer at Chinook Therapeutics, Inc. from 2021 to 2023, and Senior Director-Discovery & Translational Biology at Ardelyx, Inc. Education includes a doctorate from Michigan State University and an undergraduate degree from Murdoch University.
Andrew King active positions
| Companies | Position | Start |
|---|---|---|
| JADE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 28/04/2025 |
Former positions of Andrew King
| Companies | Position | End |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 09/08/2023 |
| ARDELYX, INC. | Corporate Officer/Principal | - |
Training of Andrew King
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Michigan State University
Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Murdoch University
Murdoch University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ardelyx, Inc.
Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes medicines for kidney diseases | Health Technology |
- Stock Market
- Insiders
- Andrew King
















